CoChat

Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies

Open access
Hu, Jie, Peng, Pai, Wang, Kai, Fang, Liang, Luo, Fei-yang, Jin, Ai-shun, Liu, Bei-zhong, Tang, Ni, Huang, Ai-long · 2021 · Cellular & Molecular Immunology

Published version of a preprint

Cited by 112

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

SARS-CoV-2 Spike-specific antibodies contribute the majority of the neutralizing activity in most convalescent human sera. Two SARS-CoV-2 variants, N501Y.V1 (also known as B.1.1.7 lineage or VOC-202012/01) and N501Y.V2 (B.1.351 lineage), reported from the United Kingdom and South Africa, contain several mutations in the receptor binding domain of Spike and are of particular concern. To address the infectivity and neutralization escape phenotypes potentially caused by these mutations, we used SARS-CoV-2 pseudovirus system to compare the viral infectivity, as well as the neutralization activities of convalescent sera and monoclonal antibodies (mAbs) against SARS-CoV-2 variants. Our results showed that N501Y Variant 1 and Variant 2 increase viral infectivity compared to the reference strain (wild-type, WT) in vitro. At 8 months after symptom onset, 17 serum samples of 20 participants (85%) retaining titers of ID50 >40 against WT pseudovirus, whereas the NAb titers of 8 samples (40%) and 18 samples (90%) decreased below the threshold against N501Y.V1 and N501Y.V2, respectively. In addition, both N501Y Variant 1 and Variant 2 reduced neutralization sensitivity to most (6/8) mAbs tested, while N501Y.V2 even abrogated neutralizing activity of two mAbs. Taken together the results suggest that N501Y.V1 and N501Y.V2 reduce neutralization sensitivity to some convalescent sera and mAbs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41423-021-00648-1

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 6

  1. Peng, P. et al. Changes in the humoral immunity response in SARS-CoV-2 convalescent patients over 8 months. Cell. Mol. Immunol. 2021. https://doi.org/10.1038/s41423-020-00605-4. · DOI
  2. Zhang, J. et al. COVID-19 reinfection in the presence of neutralizing antibodies. Natl Sci. Rev. 2021. https://doi.org/10.1093/nsr/nwab006. · DOI
  3. Han, X. et al. A rapid and efficient screening system for neutralizing antibodies and its application for the discovery of potent neutralizing antibodies to SARS-CoV-2 S-RBD. bioRxiv 2020. https://doi.org/10.1101/2020.08.19.253369. · DOI
  4. Hu, J. et al. Development of cell-based pseudovirus entry assay to identify potential viral entry inhibitors and neutralizing antibodies against SARS-CoV-2. Genes Dis. 7, 551–557 (2020). · DOI
  5. Rees-Spear, C. et al. The impact of Spike mutations on SARS-CoV-2 neutralization. bioRxiv 2021. https://doi.org/10.1101/2021.01.15.426849. · DOI · Paper page
  6. Kemp, S. et al. Neutralising antibodies in Spike mediated SARS-CoV-2 adaptation. medRxiv 2020. https://doi.org/10.1101/2020.12.05.20241927. · DOI

Cited by

See all 112

Metadata

Authors
Hu, J., Peng, P., Wang, K., Fang, L., Luo, F.-Y., Jin, A.-S., Liu, B.-Z., Tang, N., & Huang, A.-L.
Venue
Cellular & Molecular Immunology
Published
2021-02-25
Volume
18
Issue
4
Pages
1061-1063
ISSN
  • 1672-7681 (ISSN-L)
  • 2042-0226
OpenAlex
W3130984893
Cited by
112
References
7
FWCI
7.77
Type
journal article
Language
en
Open access
bronze
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies. https://app.cochat.ai/papers/10.1038/s41423-021-00648-1
The paper
Hu, J., Peng, P., Wang, K., Fang, L., Luo, F.-Y., Jin, A.-S., Liu, B.-Z., Tang, N., & Huang, A.-L. (2021). Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies. Cellular & Molecular Immunology. https://doi.org/10.1038/s41423-021-00648-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.